Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Merck KGaA, Pfizer’s cancer drug Bavencio gets EU nod

Written by: | no-reply@reuters.com | Dated: Thursday, September 21st, 2017

 

FRANKFURT (Reuters) – European regulators on Thursday granted market approval for Merck KGaA and Pfizer’s immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.

In May, Bavencio was approved by the U.S. Food and Drug Administration to treat bladder cancer and in March to treat Merkel cell carcinoma.

Bavencio, also known as avelumab, belongs to a class of drugs called PD-L1 or PD-1 inhibitors that help the immune system attack cancer by blocking a mechanism tumors use to evade detection.

 

Reporting by Ludwig Burger; Editing by Maria Sheahan

 

Reuters source:

http://www.reuters.com/article/us-merck-bavencio/merck-kgaa-pfizers-cancer-drug-bavencio-gets-eu-nod-idUSKCN1BW0V3

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation